HOUSTON, Nov. 5, 2026 /PRNewswire/ — ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced two publications providing new nonclinical evidence and scientific insights into the ability of its novel stimulator of interferon genes (STING) agonist, IMGS-203, to remodel the tumor microenvironment and enhance antitumor activity in combination...
https://bioadvance.com/immunogenesis-announces-two-publications-highlighting-the-potential-of-imgs-203-a-novel-stimulator-of-interferon-genes-sting-agonist-to-overcome-tumor-immune-resistance-and-enhance-antitumor-effic/?utm_source=rss&utm_medium=rss&utm_campaign=immunogenesis-announces-two-publications-highlighting-the-potential-of-imgs-203-a-novel-stimulator-of-interferon-genes-sting-agonist-to-overcome-tumor-immune-resistance-and-enhance-antitumor-effic